Clinical Trials Logo

Clinical Trial Summary

Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when 3 different IMPs are given as monotherapy or as combination therapy. These would be administered in the "window of opportunity", prior to nephrectomy in surgically resectable renal cell cancer


Clinical Trial Description

A Phase 2, multi-arm, multicentre, non-randomised, proof-of-mechanism (single and combination IMPs) trial using a Bayesian adaptive design. A multi-centre trial. 2 centres initially planned - this may be reduced or increased in order to recruit the required number of participants. Up to sixty (60) patients with surgically resectable renal cell cancer (Stage M0/M1). Up to twelve (12) participants will be registered for each of the single treatment arms and up to twenty (20) participants for the combination treatment arm(s) as per the Bayesian adaptive design. The trial duration consists of a 28 day screening period, a minimum of 2 weeks oral IMP (Olaparib and/or Cediranib) treatment or a single dose of durvalumab alone or in combination in the window-of-opportunity period prior to surgery (nephrectomy or partial nephrectomy) performed as standard of care. Participants will continue oral IMP treatment up until surgery (stopping when indicated for surgical safety reasons). As such treatment duration will be variable and an optional 21 day telephone assessment will take place for patients who remain on IMP. Patients will then be reviewed in the surgical follow-up clinic at 6 weeks and 3 months post-surgery as standard of care. For patients on monotherapy or combination Olaparib and Cediranib IMP, response will be measured using DCE-MRI (Ktrans), defining reduced tumour capillary permeability. For patients on monotherapy Durvalumab, or combination Olaparib and Durvalumab, response will be measured using CD8 positive T cells. Additional safety outcomes will be assessed, along with the tumour response and various biological measures that would indicate drug mechanistic response. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03741426
Study type Interventional
Source Cambridge University Hospitals NHS Foundation Trust
Contact CCTU Cancer Theme
Phone 01223 256364
Email cctu.cancer@addenbrookes.nhs.uk
Status Recruiting
Phase Phase 2
Start date July 27, 2020
Completion date November 30, 2025

See also
  Status Clinical Trial Phase
Completed NCT01392729 - An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA) N/A
Completed NCT00694096 - Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response Phase 1
Completed NCT00520403 - A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. Phase 2
Completed NCT00216801 - Relationship of Ochratoxin A to Upper Urologic Cancers N/A
Completed NCT00172003 - Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Phase 4
Completed NCT02493751 - A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100) Phase 1
Recruiting NCT01967407 - IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy. Phase 1/Phase 2
Completed NCT00509704 - Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma N/A
Terminated NCT05061537 - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT04535921 - Fear of Cancer Recurrence in Genitourinary Cancer
Recruiting NCT04620603 - Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer Phase 1/Phase 2
Completed NCT01829841 - A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer Phase 2
Completed NCT01122615 - Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) Phase 1
Completed NCT00979329 - Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST N/A
Active, not recruiting NCT02429440 - Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides Phase 1/Phase 2
Recruiting NCT06362369 - A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Phase 1/Phase 2
Active, not recruiting NCT02684006 - A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Phase 3
Completed NCT02375776 - Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention N/A
Completed NCT01598597 - An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) N/A
Completed NCT00465179 - Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer Phase 2